ReviewRespiratory research2016
Novel biomarkers for pulmonary arterial hypertension.
Review in Respiratory research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- A novel role for decadienyl-L-carnitine in pulmonary vascular remodeling and the underlying interventional mechanism of osthole.Chinese medicine · 2026Article
- Inflammatory Biomarkers and Serum Fatty Acids in High-Risk Populations: A Research Protocol.International journal of sciences, basic and applied research · 2026Article
- Specific Genes and microRNAs as Novel Diagnostic Biomarkers for the Potential Progression of Pulmonary Arterial Hypertension.Iranian journal of public health · 2025Article
- Can Plasma ADAMTS13 Differentiate Patients With Pulmonary Arterial Hypertension From Other Forms of Pulmonary Hypertension and Dyspnea Control Patients.CHEST pulmonary · 2025Article
- Article
- Investigating the causal relationship between human blood metabolites and pulmonary hypertension: a two-sample Mendelian randomization study.Frontiers in cardiovascular medicine · 2024Article
- Application of homocysteine as a non-invasive and effort-free measurements for risk assessment of patients with pulmonary hypertension.Cardiology journal · 2024Article
- Biomarkers in Pulmonary Arterial Hypertension.Diagnostics (Basel, Switzerland) · 2022Review
- MircoRNA in Extracellular Vesicles from Patients with Pulmonary Arterial Hypertension Alters Endothelial Angiogenic Response.International journal of molecular sciences · 2022Article
- A Nomogram for Predicting Patent Foramen Ovale-Related Stroke Recurrence.Frontiers in neurology · 2022Article
- An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers.Frontiers in cardiovascular medicine · 2022Review
- Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA.Frontiers in cardiovascular medicine · 2022Review
- Ventricular Function and Cardio-Ankle Vascular Index in Patients With Pulmonary Artery Hypertension.Vascular health and risk management · 2022Article
- Pulmonary Arterial Hypertension: Emerging Principles of Precision Medicine across Basic Science to Clinical Practice.Reviews in cardiovascular medicine · 2022Article
- Article
- Non-Invasive Assessment of Endothelial Dysfunction in Pulmonary Arterial Hypertension.Mediterranean journal of rheumatology · 2021Review
- Prognostic Significance of Systemic Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Idiopathic Pulmonary Hypertension.Vascular health and risk management · 2021Article
- Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.Journal of experimental pharmacology · 2021Review
- Prognostic Significance of Red Cell Distribution Width in Idiopathic Pulmonary Fibrosis and Combined Pulmonary Fibrosis Emphysema.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Article
- Donepezil Ameliorates Pulmonary Arterial Hypertension by Inhibiting M2-Macrophage Activation.Frontiers in cardiovascular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Pulmonary arterial hypertension is a deadly disease characterized by elevated pulmonary arterial pressures leading to right ventricular hypertrophy and failure. The confirmatory gold standard test is the invasive right heart catheterization. The disease course is monitored by pulmonary artery systolic pressure measurement via transthoracic echocardiography. A simple non-invasive test to frequently monitor the patients is much needed. Search for a novel biomarker that can be detected by a simple test is ongoing and many different options are being studied. Here we review some of the new and unique pre-clinical options for potential pulmonary hypertension biomarkers. These biomarkers can be broadly categorized based on their association with endothelial cell dysfunction, inflammation, epigenetics, cardiac function, oxidative stress, metabolism,extracellular matrix, and volatile compounds in exhaled breath condensate. A biomarker that can be detected in blood, urine or breath condensate and correlates with disease severity, progression and response to therapy may result in significant cost reduction and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.